ÚHKT - Ústav hematologie a krevní transfuze
Úsek pro vědu a výzkum

Academic clinical evaluations

UHKT-CAML-NK-01
EudraCT: 2017-001119-35

"Adoptive transfer of haploidentical ex vivo expanded NK cells to patients with refractory or relapsed acute myeloid leukemia within allogeneic hematopoietic stem cell transplantation from a haploidentical related donor after a sequential conditioning protocol. Monocentric, open-label phase IIa dose escalation study."

Completed

UHKT-VSL-CCS-01
EudraCT: 2018-004789-32

"Efficacy of manufacturing, clinical safety and efficacy of virus-specific T lymphocytes isolated on the CliniMACS Prodigy® device using the Cytokine Capture system for patients after allogeneic transplantation."

Completed

TCB-202-001
EudraCT: 2018-000409-22

"Clinical evaluation of safety and efficacy of allogeneic γδ T lymphocytes expanded ex vivo (OmnImmune®) in patients with relapsed or resistant acute myeloid leukemia (AML) who cannot or are unwilling to undergo high-dose salvage chemotherapy and/or allogeneic hematopoietic stem cell transplantation. Open-label phase I dose escalation study."
https://pubmed.ncbi.nlm.nih.gov/36863897/

Completed

UHKT-CAR19-01
EudraCT: 2018-004789-32
EU CT Number: 2024-510815-30-00
Clinicaltrials.gov ID: NCT05054257

"Clinical evaluation of safety and efficacy of autologous CART19 lymphocytes in patients with relapsed or refractory acute B-lymphoblastic leukemia (B-ALL) or with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). Open-label phase I dose escalation study."

Open

UHKT-CAR123-01
EU CT Number: 2022-503165-30-00

"Safety and efficacy of autologous T lymphocytes with chimeric antigen receptor anti-CD123 in patients with relapsed or refractory CD123 positive hematological malignancy. Open-label phase I dose escalation study."

Open